Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Income from Continuing Operations (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Income from Continuing Operations for 5 consecutive years, with 4493000.0 as the latest value for Q4 2020.

  • Quarterly Income from Continuing Operations rose 57.55% to 4493000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was 46980000.0 through Dec 2020, up 0.74% year-over-year, with the annual reading at 3110000.0 for FY2025, 108.77% up from the prior year.
  • Income from Continuing Operations for Q4 2020 was 4493000.0 at Forte Biosciences, up from 5008000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 383000.0 in Q3 2018, with the low at 34754000.0 in Q2 2020.
  • Average Income from Continuing Operations over 5 years is 10787900.0, with a median of 9088000.0 recorded in 2017.
  • The sharpest move saw Income from Continuing Operations skyrocketed 96.15% in 2018, then tumbled 4791.64% in 2019.
  • Over 5 years, Income from Continuing Operations stood at 8461000.0 in 2016, then dropped by 28.08% to 10837000.0 in 2017, then tumbled by 80.89% to 19603000.0 in 2018, then soared by 46.01% to 10583000.0 in 2019, then soared by 57.55% to 4493000.0 in 2020.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 4493000.0, 5008000.0, and 34754000.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.